Providence Health & Services
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private, Subsidiary
- Established
- 1859-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.providence.org
SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 13
- Registration Number
- NCT04417699
- Locations
- πΊπΈ
University of California, Irvine, Orange, California, United States
πΊπΈColumbia University Irving Medical Center/NYPH, New York, New York, United States
πΊπΈProvidence Portland Medical Center, Portland, Oregon, United States
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Breast CancerBreast Neoplasms
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 12
- Registration Number
- NCT04373031
- Locations
- πΊπΈ
Providence Portland Medical Center, Portland, Oregon, United States
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
Phase 4
Suspended
- Conditions
- 2019 Novel CoronavirusSARS-CoV-2COVID-19Corona Virus Infection2019-nCoV
- Interventions
- Dietary Supplement: Vitamin C
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 13
- Registration Number
- NCT04334967
- Locations
- πΊπΈ
Portland Providence Medical Center, Portland, Oregon, United States
Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
Phase 3
Completed
- Conditions
- Multiple SclerosisInfusion Reaction
- Interventions
- Drug: cetrizine
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 19
- Registration Number
- NCT04175834
- Locations
- πΊπΈ
Providence Neurological Specialties West, Portland, Oregon, United States
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Phase 2
Active, not recruiting
- Conditions
- BRAF V600E Mutation PresentStage IVA Differentiated Thyroid Gland Carcinoma AJCC v8Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8Metastatic Thyroid Gland CarcinomaRefractory Thyroid Gland CarcinomaStage IVB Differentiated Thyroid Gland Carcinoma AJCC v8BRAF NP_004324.2:p.V600M
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 24
- Registration Number
- NCT04061980
- Locations
- πΊπΈ
Providence Portland Medical Center, Portland, Oregon, United States
Achieving the Quadruple Aim by Reducing Burnout
Not Applicable
Completed
- Conditions
- Burnout, Professional
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 341
- Registration Number
- NCT03746574
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Phase 1
Terminated
- Conditions
- GlioblastomaCancer of BrainGlioblastoma MultiformeBrain Tumor
- Interventions
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 7
- Registration Number
- NCT03705351
- Locations
- πΊπΈ
University of California San Francisco, San Francisco, California, United States
πΊπΈProvidence St. Vincent Medical Center, Portland, Oregon, United States
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Phase 2
Active, not recruiting
- Conditions
- Breast Neoplasm FemaleBreast CancerBreast CarcinomaBreast Tumor
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 30
- Registration Number
- NCT03650894
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈProvidence Oncology & Hematology Care Clinic - Eastside, Portland, Oregon, United States
Melatonin in Patients With Multiple Sclerosis (MS).
Early Phase 1
Completed
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: 5 mg Melatonin
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 30
- Registration Number
- NCT03498131
- Locations
- πΊπΈ
Providence MS Center, Portland, Oregon, United States
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Phase 1
Active, not recruiting
- Conditions
- Head and Neck CancerHead and Neck Squamous Cell CarcinomaMelanomaCell Cancer, SquamousCarcinoma, Squamous Cell
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 35
- Registration Number
- NCT03336606
- Locations
- πΊπΈ
Providence Portland Medical Center, Portland, Oregon, United States